Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (2303)	4/8/2005 10:49:40 PM
From: tom pope	Respond to of 12215

That sounds like a substantial plate. Thanks, Zeta.

To: zeta1961 who wrote (2303)	4/9/2005 2:21:43 PM
From: tom pope	Respond to of 12215

This is what the Aria site says about the litigation - doesn't help me much but others may have a point of view. The copy function translates the kappa as a Q mark. This is the address: ariad.com NF-?B Highlights We have an exclusive license to pioneering technology and patents related to certain NF-?B treatment methods, and the discovery and development of drugs that regulate NF-?B cell-signaling activity. Regulation of NF-?B cell-signaling activity may be useful in treating certain medically important disorders. • The Science. Dr. David Baltimore, formerly director of the Whitehead Institute for Biomedical Research, Dr. Phillip Sharp of the Massachusetts Institute of Technology, and Dr. Thomas Maniatis of Harvard University, together with a team of scientists in their respective laboratories, discovered a family of genes that encode proteins they called NF-?B and I-?B, its inhibitor; the critical role played by NF-?B cell signaling in regulating cellular processes involved in various difficult-to-treat diseases; methods to identify compounds to regulate NF-?B cell-signaling activity; and methods of treating disease by inhibiting NF-?B. NF-?B can be generally thought of as a "biological switch" that can be turned off using these methods to treat disorders, such as inflammation, cancer, sepsis and osteoporosis. • The Patents. We have an exclusive license to a portfolio of four issued patents relating to NF-?B, three in the United States and one in Europe. The most recent U.S. patent, issued in June 2002, contains a range of focused claims to methods useful for treating various disease conditions through modulation of NF-?B activity. In June 2002, we and our inventors’ academic institutions filed a lawsuit against Eli Lilly and Company alleging infringement of certain claims of this patent by Lilly through sales of its osteoporosis drug, Evista®, and its septic shock drug, Xigris®. • The Licensing Program. We permit broad use of our NF-?B intellectual property at no cost by investigators at academic and not-for-profit institutions to conduct non-commercial research. Our goal is to license our NF-?B technology to pharmaceutical and biotechnology companies conducting research on the discovery of drugs that modulate NF-?B cell signaling and/or marketing such drugs. Bristol-Myers Squibb Company and DiscoveRx Corporation, a high-throughput screening company, have entered into research and development licenses for our NF-?B intellectual property. Page 2 • The Business Implications. The use of many currently marketed drugs and products in development, in addition to the two highlighted in the Lilly litigation, are examples of NF-?B treatment methods which may be covered by our NF-?B patents. While we cannot predict today the revenue stream that may ultimately result from its NF-?B patent portfolio, our share of any proceeds from Lilly or any other company that licenses our intellectual property portfolio will be used to fund the development of our innovative treatments for cancer and other life-threatening diseases – supporting our efforts to build a science-driven, product development company focused primarily on cancer. For updated information about the proceedings in our case against Lilly, see our most recent filings with the Securities and Exchange Commission (including reports on Forms 8-K, 10-K, and 10-Q). (Last updated: March 10, 2004)